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Abstract Human BST-1, a bone marrow stromal cell surface molecule, is a GPI-anchored protein that facilitates the growth of pre-B cells. The 
deduced amino acid sequences of human and mouse BST-1 show around 30% homology with those of CD38 and Aptysia ADP ribosyl cyclase. 
Therefore, like CD38, BST-1 might possess ADP ribosyl cyclase activity. Here, we report the establishment of a stable transformant CHO cell line, 
which secretes truncated human soluble BST-1, and show that purified soluble BST-1 displays both ADP ribosyl cyclase and cADPR hydrolase 
activities. 
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1. Introduction 
We have recently isolated the cDNA for a novel surface 
molecule BST-1 (bone marrow stromal cell antigen 1) expressed 
on human bone marrow stromal cell lines, and showed that 
BST-1 is a glycosyl-phosphatidylinositol (GPI)-anchored pro- 
tein that facilitates the stroma cell-dependent growth of pre-B 
cell line [l]. The expression of BST-I was enhanced in rheuma- 
toid arthritis-derived bone marrow stromal cell lines compared 
with healthy donor-derived ones. In addition, BST-1 mRNA 
was detected in various tissues including placenta, lung, liver 
and kidney, where its physiological roles, however, are still 
unclear. The deduced amino acid sequence of both human and 
murine BST-1 showed around 30% homology with those of 
Aplysiu ADP ribosyl cyclase and CD38 [1,2]. The molecular 
cloning of murine BST-1 [2] and murine BP-3 [3] showed that 
BST-1 is identical with BP-3 which was originally identified as 
a molecule expressed on pre-B cells transformed either by Abel- 
son murine leukemia virus or an erb B oncogene construct [4]. 
CD38, which is expressed in lymphocytes and various tissues, 
bears a 31% homology to Aplysia ADP ribosyl cyclase [5], and 
possesses both ADP ribosyl cyclase and cyclic ADP ribose 
(cADPR) hydrolase activities [&12]. Anti-CD38 antibody in- 
duces an increase of intracellular Ca2’ and an immunoglobulin- 
independent activation and proliferation of B cells [12,13]. It 
has been suggested that this activation is partially mediated by 
the ADP ribosyl cyclase activity of CD38 that catalyzes the 
synthesis of cADPR from NAD, since cADPR but not ADP 
ribose (ADPR) augmented the stimulatory effect of anti-CD38 
mAb on B cells [12]. Cyclic ADPR is known to serve as an 
endogenous second messenger that regulates the mobiliza- 
tion of intracellular calcium [14-161, but the mechanism by 
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which extracellular cADPR stimulates B cells remains to be 
clarified. 
In this study, we first designed and purified a recombinant 
human soluble BST-1 molecule (sBST-1) expressed in CHO 
cells, and then evaluated its enzymic activity as ADP ribosyl 
cyclase. 
2. Materials and methods 
2.1. Preparation of soluble BST-I 
In order to express human BST-1 in its soluble form, the cDNA 
encoding amino acids l-297 was amplified by polymerase chain reac- 
tion (PCR) using two primers, one sense (5-‘CCGAATTCCACCAT- 
GGCGGCCCAGGGGTGCGCGGCA-3’) and one antisense (5’-GG- 
TGATCATTAATAAAGACTTGGGGCTTTTCTTT-3’), containing 
respectively aKozak consensus equence [17] and a termination codon. 
After digestion by EcoRI and BctI, the PCR product was placed under 
the control of the EF-1 a-promoter in a pCHO-1 plasmid containing 
dihydrofolate reductase (DHFR) cDNA as a selective marker, thus 
yielding pCHO-BSTI EC. The expression vector (40 pg) was linearized 
by PvuI and introduced into CHO cells (7 x lo6 cells, DHFR-) by 
electroporation (1.6 kV, 25 pF) using a Gene-Pulser (Bio-Rad). The 
sBST-1 secreted by transformants was analyzed by a Biosensor 
(BIAcore, Pharmacia), in which RF3 (3 pg) [I], a mouse anti-human 
BST-1 monoclonal antibody, was immobilized on a sensor chip. After 
sequential gene amplification in the presence of 20 nM and 100 nM 
methotrexate, a CHO clone (49) highly expressing sBST-1 was estab- 
lished, and cultured in ASF104 serum-free medium (Ajinomoto). After 
3 or 4 days of incubation, the culture supernatant was collected, concen- 
trated, and exchanged for binding buffer (10 mM Tris-HCl, pH 8.6) 
using an Ultra-Filtration miniset Omega 3K (Filtron). The solution was 
then applied onto a DE52 column (Whatman) equilibrated with the 
binding buffer. The column was washed with 5 bed volumes of the same 
buffer, and eluted with 0.1 M NaCl in 10 mM Tris, pH 8.6. The elution 
fraction corresponding to the largest absorption peak at 280 nm was 
collected, concentrated, and the buffer exchanged for RCA buffer 
(10 mM Tris-HCI, pH 7.6) using a Centriprep-30 (Grace). The fraction 
was then applied onto a RCA120 column (Hohnen) equilibrated with 
the RCA buffer. The column was washed with 10 bed volumes of RCA 
buffer, and eluted with RCA buffer containing 200 mM galactose. The 
fraction corresponding to the largest absorption peak was collected, 
and concentrated. The protein sample was finally analyzed by SDS- 
PAGE, and its N-terminal amino acid sequence determined by a Model 
476A protein sequencer (Applied Biosystems). Glycosylation analysis 
was performed with N-glycanase (Genzyme) according to the manufac- 
turers procedure. 
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2.2. Detection of ADP ribosyl cyclase activity 
ADP ribosyl cyclase and cADPR hydrolase activities were measured 
through the production of cADPR from NAD and of ADPR from 
cADPR, respectively. Assays for these activities were essentially per- 
formed under the following conditions. First, sBST-1 (10 &ml) was 
incubated at 37°C with 0.2 mM NAD (or 20 uM cADPR) in 50 mM 
MES buffer, pH 6.0, containing 1 mM ZnCl,.‘Aliquots were collected 
at successive time intervals for time course analysis, and after 2 h for 
the studies on the effects of pH or metal ions. Soluble BST-1 inactivated 
by heating at 96°C for 2 h was used as a negative control. NAD, 
cADPR and ADPR present in the samples were then separated using 
a PL-SAX 1OOOA HPLC column (50 x 4.6 mm; Polymer Laboratories) 
with a linear gradient of 0.02 M to 0.51 M NH&O, for 15 min, and 
a flow rate of 0.5 ml/min. Standard samples were purchased from Sigma 
RJAD and ADPR) and Amersham (cADPR). and aDDlied under the 
II . . 
same conditions. Concentrations of each product were represented as 
the integrated percentage of their peak areas on HPLC by monitoring 
their absorption at 260 nm. 
3. Results 
3. I. Characterization of sBST-1 
By subcloning BST-1 cDNA into a pCHO-1 plasmid and 
transfecting it into CHO cells, we established a CHO cell line 
that produces sBST-1 at a concentration of approximately 30 
,@ml. Using two-step column chromatography, successively 
on anion-exchange and lectin columns, sBST-1 was purified as 
a broad band with an apparent molecular weight of 43 kDa 
after SDS-PAGE and Coomassie brilliant blue staining (Fig. 1, 
lane 1). The molecular weight was not consistent with the pre- 
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Fig. 1. Analysis of N-linked glycosylation. Purified sBST-1 (lane 1) and 
N-glycanase treated sBST-1 (lane 2) were analyzed by SDS-poly- 
acrylamide gel electrophoresis under reducing conditions. Protein size 
markers are indicated on the left side. 
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Fig. 2. Time course analysis of NAD metabolization by sBST-1. Puri- 
fied sBST-1 (50 @ml) was incubated with 0.2 mM NAD in 50 mM 
MES buffer at pH 6.0 containing 1 mM ZnCl, at 37’C. Aliquots 
(200 ~1) were collected at the indicated times, and analyzed by anion- 
exchange HPLC as described in section 2. Concentrations of NAD (o), 
cADPR (0) and ADPR @) are represented as the percentage of their 
peak areas on HPLC. 100% represents the total area of 3 peaks. 
dieted molecular weight of 30.2 kDa based on the deduced 
amino acid sequence, suggesting the presence of posttransla- 
tional modifications. Indeed, the presence of four potential 
N-linked glycosylation sites on this sequence suggested that 
sBST-1 is heavily glycosylated. This was confirmed by N-glyca- 
nase treatment of sBST-1 which produced a sharp single band 
at approximately 31 kDa (Fig. 1, lane 2). 
We also identified the first eleven amino acids of BST-1 
N-terminal sequence as Arg-Trp-Arg-Ala-Glu-Gly-Thr-Ser- 
Ala-His-Leu, which were completely identical to the Arg33- 
Leu43 deduced amino acid sequence of BST-1. This sequence 
analysis revealed that the sBST-1 precursor peptide is cleaved 
between Ala3* and Arg33, which corresponds well to the poten- 
tial cleavage site (second candidate site) determined by com- 
puter analysis [ 181. 
3.2. Enzymic activity 
Soluble BST-1 was incubated with NAD or cADPR, and its 
enzymic activities were determined by HPLC by measuring the 
reaction products, cADPR or ADPR. Time course experiments 
showed that sBST-1 produced both cADPR and ADPR from 
NAD, suggesting that sBST-1 possesses two enzymic activities, 
ADP ribosyl cyclase and cADPR hydrolase (Fig. 2). Evidence 
for each enzymic activity was further supported by comparison 
with heat-inactivated sBST-1 (Fig. 3). Native sBST-1 was able 
to generate cADPR from NAD, and ADPR from cADPR, 
whereas heat-inactivated sBST-1 did not show any enzymic 
activity. 
The effect of pH on the ADP ribosyl cyclase activity of 
sBST-1 was examined next. Enzymic activity of sBST-1 in the 
presence of EDTA was maximum at pH 4.0 and decreased at 
higher pH (Fig. 4a). By contrast, in the presence of Zn*‘, sBST- 
1 showed an almost equal enzymic activity between pH 4.0 and 
pH 6.5 (Fig. 4b), suggesting that sBST-1 may require a metal 
ion for its enzymic activity. 
The effect of metal ions on sBST-1 enzymic activity was 
further examined. Zn*’ and Mn*’ remarkably increased the 
ADP ribosyl cyclase activity, up to 5-fold compared to the 
control (Fig. 5a). Cyclic ADPR hydrolase activity was also 
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Fig. 3. Analysis of ADP ribosyl cyclase and cADPR hydrolase activi- 
ties. Native sBST-1 (lO,ug/ml) (0, n ) was incubated with 0.2 mM NAD 
(a) or 20 PM cADPR (b) in 50 mM MES buffer, pH 6.0, containing 
1 mM ZnCl, at 37°C. Heat-inactivated sBST-1 (0 q ) used as negative 
control was tested in parallel. Aliquots (200 ~1) were collected at time 
0 and after 30,60 and 120 min, and analyzed by anion-exchange HPLC 
as described in section 2. 100% represents the total area of 3 peaks of 
NAD, cADPR and ADPR in (a) and 2 peaks of cADPR and ADPR 
in (b). 
increased by Zn2’ and Mn2+ (Fig. 5a,b). Inversely, Cu2+ showed 
an inhibitory effect on both cyclase activity and hydrolase activity, 
while MgZ’ and Ca2’ did not have any significant influence. 
4. Discussion 
4.1. Characterization of sBST-1 
We have established a CHO cell line that produces large 
quantity of human sBST-1, and successfully obtained suffi- 
ciently pure sBST-1 to study its biological activities. Since the 
ratio of sBST-1 in serum-free conditioned medium was very 
high (approximately 50% to 60% of the total proteins, data not 
shown), purification was relatively easy. Purified sBST-1 gave 
a broad band with an apparent molecular weight of 43 kDa on 
SDS-PAGE, whereas sBST-1 treated with N-glycanase gave a 
sharp single band at approximately 31 kDa, indicating that 
sBST-1 is a glycosylated protein. Since the difference in molec- 
ular weight is about 12 kDa, all four potential N-linked glyco- 
sylation sites can be glycosylated. In addition, the N-terminal 
sequence analysis revealed that the sBST-1 precursor peptide 
is cleaved between Ala32 and Arg33, and no other minor cleav- 
age site was detected. The broad 43 kDa band must thus be due 
to the heterogeneity of N-linked carbohydrates, and not to that 
of signal peptide cleavage sites. We previously reported that the 
putative cleavage site was between Gly2* and Glyz9, and pre- 
dicted that the mature membrane form of BST-1 consists of 290 
amino acids [l]. However, the N-terminal sequence analysis 
suggests rather that this form of BST-1 contains only 286 amino 
acids. 
4.2. Enzymic activity of sBST-1 
As expected from the sequence homology with CD38 and 
Aplysia ADP ribosyl cyclase, sBST-1 possessed ADP ribosyl 
cyclase and cADPR hydrolase activities. The combined effect 
of these two enzymic activities would thus result in conversion 
of NAD to cADPR, and then hydrolysis of cADPR to ADPR. 
Previous studies showed that the optimum pH for CD38 
enzymic activities was 6.5 and that the cyclase activity of CD38 
on the erythrocyte membrane was increased by the addition of 
Zn” or Cu*+ [7]. Most recently, amino acid residues 119 and 
201 of human CD38 have been demonstrated to play a crucial 
role in the cADPR synthesis and hydrolysis [19]. The corre- 
sponding amino acid residues of CysLL9 and Cyszo’ in the human 
CD38 are Arg and Ser, respectively, in both human (Arglo3 and 
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Fig. 4. Effect of pH on the catalytic activities of sBST-1. Purified 
sBST-1 (50 @ml) was incubated with 0.2 mM NAD in 50 mM MES 
buffer adjusted to the appropriate pH, in the presence of 1 mM EDTA 
(a) or 1 mM ZnCl, (b) for 2 h at 37 “C. Concentrations of NAD (o), 
cADPR (0) and ADPR (H) are represented as the percentage of their 
peak area on HPLC. 100% represents the total area of 3 peaks. 
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Fig. 5. Effect of various metal ions on ADP ribosyl cyclase and cADPR 
hydrolase activities. Purified sBST-l(20 &ml) was incubated with 
0.2 mM NAD (a) or 20 PM cADPR (b) in 50 mM MES buffer pH 7.0 
containing 1 mM of various metal ions as indicated, for 2 h at 37 ‘C. 
Concentrations of generated cADPR (gray boxes) and ADPR (open 
boxes) are represented asthe percentage of their peak area on HPLC. 
SerlE4) and mouse (Argg6 and Ser’77) BST-1 [1,2]. In the present 
study, the cyclase activity of sBST-1 in the absence of metal ions 
was scarcely detected around neutral pH (Fig. 4a), in agreement 
with Dong et al. [3] who did not detect any enzymic activity in 
BP-3 expressed on cell surface. This is consistent with the re- 
sults that a BST-1 type mutant CD38 (Cys”’ to Arg) showed 
neither ADP ribosyl cyclase nor cADPR hydrolase activity [19]. 
The pH dependent changes in the enzymic activity of sBST-1 
(Fig. 4a) may account for the amino acid residues of this type 
of proteins including Argio3 and/or SerlE4 in sBST-1. In the 
presence of Zn*+, sBST-1 showed no pH dependency between 
pH 4.0 and pH 6.5, in which range the optimal enzymic activity 
was retained (Fig. 4b). In the extracellular egion, ten Cys, one 
Glu, one His and one Asp residues were completely conserved 
among Aplysia ADP ribosyl cyclase [20,21], human CD38 [22], 
mouse CD38 [23], rat CD38 [24], human BST-1 [l] and mouse 
BST-l/BP-3 [2,3] which may constitute a new family. All mem- 
bers of this family may physiologically contain a metal ion in 
a common manner, since Cys, His, Glu and Asp can readily 
have coordinated binding to cations. 
The addition of Cu*+ inhibited both the cyclase and hydro- 
lase activities of sBST-1, whereas it increased the cyclase activ- 
ity of CD38 on the erythrocyte membrane [7]. This discrepancy 
may prove to be useful in discriminating between BST-1 and 
CD38 activities. 
4.3. The enzymic and biological activities of BST-1 
BST-1, a GPI-anchored membrane protein, is expressed in 
stroma cells, whereas CD38, a type II transmembrane protein, 
is expressed in immature and activated lymphocytes, and both 
are thought to be involved in the growth and differentiation of 
lymphocytes [1,10,12,13]. It has been suggested that the physio- 
logical role of CD38 on B lymphocytes is at least in part due 
to the cyclase activity of CD38 [12]. 
It is known that cADPR mobilizes internally stored Ca*’ as 
effectively as inositol 1,4,5-triphosphate (IP3). The Ca*’ release 
mechanism by cADPR, however, is totally distinct from the IP3 
pathway and related to the Ca*‘-induced Ca” release system 
[1416]. Nevertheless, the function of ADPR still remains elu- 
sive. If BST-1 and CD38 act on the cell surface of lymphocytes 
through their enzymic activities, extracellularly produced 
cADPR requires the presence of specific cellular receptors to 
enter into the cells [25,26], although such receptors have not yet 
been identified. 
At the moment, it is completely unknown whether the en- 
zymic activity of BST-1 is involved in its support of pre-B cell 
growth. Alternatively, the enzymic activity of BST-1 may not 
be related to its effects on pre-B cell growth, but may be in- 
volved in other biological activities of cADPR, such as insulin 
release from pancreatic /?-cells, which has been demonstrated 
previously [15]. Whether the cyclase and hydrolase activities of 
BST-1 are related to the physiological function deserves further 
investigation. 
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